PFE - Pfizer's Paxlovid Demonstrates Safety But Raises Questions on Efficacy in Low-Risk Covid-19 Patients-NEJM Study | Benzinga
Wednesday, the New England Journal of Medicine published full study data from the Phase 2/3 trial of Pfizer Inc’s (NYSE:PFE) Paxlovid (Nirmatrelvir in combination with ritonavir). They shared initial data in 2022.
The study enrolled adult vaccinated patients with COVID-19 who had at least one risk factor for severe disease and patients without risk factors who had never been vaccinated or had not received a vaccine in the past year.
Participants were given either Paxlovid or a placebo.
The publication notes that the efficacy of this treatment in patients who are ...